Data Science & Medical Leadership Team
Chief Medical Officer
William K. Oh, MD, is an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. As Chief Medical Officer at Sema4, he is responsible for strategy development, scientific collaborations, clinical development programs, and the adoption of our advanced health intelligence offerings in oncology and a broad spectrum of human diseases.
Before joining Sema4, William served as Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. He was also the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at Mount Sinai. In addition to his current role at Sema4, William continues to care for his patients as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai, where he has been recognized by New York Magazine as a Best Doctor for the past decade.
Prior to joining Mount Sinai, William served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center. In addition to his roles as a widely respected clinician, researcher, and principal investigator of multiple clinical trials, William developed large clinical databases and specimen biorepositories for genitourinary cancers at both Harvard’s Dana-Farber Cancer Institute and Mount Sinai.
William has authored more than 300 articles, reviews, and book chapters related to prostate, renal, bladder, and testicular cancers. He has also edited three books on prostate cancer, and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer.
William is a graduate of Yale College and New York University School of Medicine, and completed his training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Chief Medical Officer, GeneDx
Paul Kruszka, MD, is Chief Medical Officer of GeneDx, a leader in genomic testing and analysis for rare disorders, which was acquired by Sema4 in April 2022. Paul is responsible for leading genomic research in rare diseases and promoting access to genomic medicine.
Paul is a board-certified clinical geneticist who uses genomic and precision medicine to enhance the delivery of healthcare to individuals with rare diseases. Paul’s career is motivated by the idea that genetic technology can be used to have a beneficial impact on people’s lives and that there are still many challenges to implementing genomic medicine.
Prior to working at GeneDx, Paul spent a decade at the National Institutes of Health conducting genomic research and taking care of individuals with rare genetic diseases. He is credited with the clinical and molecular delineation of multiple novel genetic conditions.
After attending medical school at the University of Michigan, Paul completed a family medicine residency at the University of Virginia. He also completed a clinical genetics residency at the National Human Genome Research Institute at the National Institutes of Health.
Chief Data Officer
Andrew Kasarskis has more than 20 years of broad leadership experience in healthcare, biotech, and academia that includes a strong focus on digital analytics and internationally recognized life sciences research.
As Chief Data Officer (CDO), Andrew is responsible for further optimizing Sema4’s health intelligence platform and orchestrating data use and data science to support research, development, and innovation.
Prior to Sema4, Andrew most recently served as Executive Vice President and Chief Data Officer of the Mount Sinai Health System, including the Icahn School of Medicine at Mount Sinai, where he was responsible for supporting patient care, education, research, and innovation through purposeful and appropriate use of the health system’s data assets. Before assuming the CDO role at Mount Sinai, he worked with Founding Director Eric Schadt, Sema4’s Founder, as Co-Director of the Icahn Institute for Genomics and Multiscale Biology and Vice Chair of the Department of Genetics and Genomic Sciences, in which he also served as Interim Chair.
Dr. Kasarskis’ collaborative research as Professor in the Departments of Genetics and Genomic Sciences and Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai focused on methods and technologies for improving health outcomes through better data acquisition and mining to support patient care decisions and therapeutic and diagnostic development. He created and applied technology across many disease and public health areas including pathogen surveillance, autoimmune conditions such as inflammatory bowel disease and asthma, viral infections, and primary prevention of chronic disease.
Prior to Mount Sinai, Andrew held leadership positions at Pacific Biosciences, Sage Bionetworks and Merck. He has published more than 90 research papers.
Andrew holds a PhD in Molecular and Cellular Biology from the University of California, Berkeley, as well as a BS in Biology and a BA in Chemistry from the University of Kentucky.
Chief Science Officer
Gustavo Stolovitzky is a world-renowned expert in computational biology, disease modeling and nano-biotechnology, with over 25 years of experience in high throughput data analysis for biology and the application of technology to solve biomedical problems.
As Chief Science Officer, Gustavo has a key role in developing the strategic research direction of the company and is responsible for advancing our platform of algorithms to help researchers, health system partners, providers and patients translate the information contained in health data into actionable knowledge.
Gustavo spent 23 years at IBM Research, where he was appointed IBM Fellow, the highest technical honor bestowed by IBM. His most recent role was the Founding Chair of the Exploratory Life Sciences Program at IBM Research and, previously, he was the Director of the Translational Systems Biology and Nanobiotechnology Program. He has authored more than 180 articles, reviews, and book chapters, and holds over 80 granted patents.
He is well known as the founder of the DREAM Challenges, where he nucleated a community of more than 25,000 researchers applying AI to biomedicine and championed the values of open science and data sharing, as well as rigorous evaluation of performance and reproducibility of algorithms. Through the DREAM Challenges and his own research, Gustavo addressed core challenges in biomedical research, with great influence in the areas of biological network inference, cancer genomics, and prediction of treatment response and disease outcome.
Chief Health Informatics Officer
Rong Chen, PhD, is an expert in translational bioinformatics. Rong has over 20 years of experience developing bioinformatics databases, methods, software, and platforms to drive clinical and research applications in the academic, software, diagnostic, and biotech industries. He has published more than 110 papers in journals such as Nature Biotechnology and The Lancet.
As Chief Health Informatics Officer, Rong leads Sema4’s informatics teams that are responsible for the structuring and management of genomic- and health-related data with health system partners, as well as the development of a health insight platform to engage researchers, clinicians, and administrators to improve the standard of care, an artificial intelligence platform to engage biopharma scientists for advanced analytics, and a genomic platform to scale up genetic testing.
Before joining Sema4, Rong was an Assistant Professor in the Department of Genetics & Genomic Sciences and Institute of Genomics & Multiscale Biology, and Director of the Clinical Genome Informatics Laboratory at Icahn School of Medicine at Mount Sinai.
Rong received his BS in Chemical Physics from the University of Science and Technology in China, his MS in Structural Biology from the Chinese Academy of Sciences, and his PhD in Bioinformatics from Boston University.
Chief Medical Officer – Reproductive Health
In addition to serving as Chief Medical Officer – Reproductive Health at Sema4, Alan B. Copperman, MD, is co-founder and a Medical Director of RMA of New York, one of the country’s largest and most prestigious IVF centers. He also serves as the Director of the Division of Reproductive Endocrinology & Infertility and the Vice-Chairman of the Department of Obstetrics, Gynecology & Reproductive Science at Icahn School of Medicine at Mount Sinai.
Alan has published numerous papers, book chapters, and abstracts on reproductive medicine and is frequently featured in print, digital media, and local and national news shows. He has been named to New York Magazine’s list of Best Doctors for 16 years in a row and has been recognized annually by Castle Connolly and SuperDocs as one of the top fertility doctors.
Senior Vice President, Molecular Oncology
Feras Hantash brings 16 years of molecular diagnostics experience to Sema4. As Senior Vice President of Molecular Oncology at Sema4, he is responsible for building and overseeing various aspects of the company’s molecular oncology test portfolio and clinical test operations, ensuring compliance with quality and proficiency testing, supporting regulatory submissions to several agencies, and providing solutions for pharma and research studies.
Feras also serves as an Adjunct Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, participating in ABMGG LGG fellowship training programs. He has multiple publications covering molecular oncology, genetics, and phenotypic markers, and holds several national and international patents in molecular diagnostics.
Before joining Sema4, Feras served as Senior Scientific Director in the Hematology/Oncology department at Quest Diagnostics Nichols Institute, where he led the research and development team in building laboratory developed tests. He also co-led the clinical operations of the department in deploying these and other tests in the U.S. and globally.
Feras received his PhD degree from the University of Texas at Austin. He completed his clinical molecular genetics fellowship training at the University of California and is board-certified in Clinical Molecular Genetics by the American Board of Medical Genetics and Genomics.
Head of Statistical Genomics
Ke Hao, ScD, leads Sema4’s development of predictive models for complex human diseases. He is also a Professor at the Icahn School of Medicine at Mount Sinai in the Department of Genetics & Genomic Sciences.
Ke’s research focuses on the genetic and environmental basis of human diseases, using translational statistical genetics and computational algorithms to mine massive datasets and deliver clinical insights.
Chief Technology Officer and Chief Information Security Officer
Shay Hassidim has more than 25 years of experience in information security, cloud computing, in-memory computing, cloud automation, software development, enterprise IT, and data strategy. He has held senior technology roles implementing large-scale projects with Fortune 500 global companies across multiple sectors.
As Chief Technology Officer and Chief Information Security Officer at Sema4, Shay is responsible for the development, implementation, and optimization of the company’s information security program. This includes policies and procedures designed to protect enterprise communications, systems, and assets from threats. Shay is also responsible for developing and maintaining Sema4’s information technology strategy and enterprise architecture, positioning the company for innovation, efficient growth, and scaling.
Shay holds a BSc in Electrical and Computer Engineering from Ben-Gurion University of the Negev in Israel with a specialization in bioinformatics and machine learning.
Senior Vice President, Health Economics & Outcomes Research
As Senior Vice President of Health Economics & Outcomes Research (HEOR) at Sema4, Mitch Higashi is responsible for defining and implementing innovative strategies that determine product value and commercialization activities for the company’s genomic solutions, algorithms, and pharma support program. Mitch is also responsible for ensuring alignment with commercial and market access strategies, including evidence generation, pricing, and reimbursement.
Prior to joining Sema4, Mitch was Vice President of HEOR at Bristol-Myers Squibb (BMS) where his department generated evidence to support market access, medical strategy, and research in oncology, hematology, immunology, and cardiovascular disease. While at BMS, Mitch was selected to present the pharma perspective on price-value assessments to Congress.
Mitch has co-authored 20 peer-reviewed papers, including for JAMA. He has also served on the Board of Directors for the University of Washington Foundation and the ISPOR Health Science Policy Council.
Mitch was awarded a grant from the National Institute of Environmental Health Sciences to conduct his doctoral thesis in pharmacogenetics and outcomes research. He is a graduate of the University of British Columbia, University of Washington, where he received his PhD in HEOR, and The Wharton School of the University of Pennsylvania.
Senior Vice President, Clinical Informatics
As SVP, Clinical Informatics, at Sema4, Li Li, MD, leads research focused on developing a common data model for electronic medical records, driving the development and improvement of clinical applications in areas including reproductive disease and newborn health. She has published extensively in the fields of precision medicine, bioinformatics, and clinical bioinformatics, with more than 90 peer-reviewed papers in top journals such as Nature Biotech, Science Translational Medicine, Journal of Clinical Investigation, PNAS, etc.
Li is also an Adjunct Assistant Professor at the Icahn School of Medicine at Mount Sinai in the Department of Medicine. She is trained as both a physician and bioinformatician, with an MD in Clinical Medicine from the Dalian Medical School in China and an MS in Bioinformatics from Boston University, as well as over 16 years of experience in industry and academia.
Chief Compliance and Privacy Officer
As Sema4’s Chief Compliance and Privacy Officer, Murali Mani is responsible for ensuring trust and transparency with patients, partners, and investors, driving policy and certifications and conducting audits to comply with key regulations, standards, and certifications.
Prior to joining Sema4 in 2020, Murali was the Director of Compliance covering privacy, security, and data governance at IBM Watson Health, where he built a quality and compliance program for an extensive portfolio of health products and services in more than ten countries. He also served as the Senior Privacy Officer for Philips Group Innovation, with responsibility for overseeing several hundred human subject studies across approximately a dozen countries.
Murali has a PhD in Mechanical Engineering from Northwestern University. He also holds Certified Information Privacy Professional (CIPP) and Certified Information Privacy Manager (CIPM) credentials from the International Association of Privacy Professionals,and Project Management Professional (PMP) credentials from the Project Management Institute.
Senior Vice President, Translational Genetics
Kenan Onel, MD, PhD, is an internationally recognized physician-scientist with deep expertise in oncology and cancer genetics. As Senior Vice President of Translational Genetics at Sema4, Ken is responsible for leading medical research in cancer genetics, integrating genetics and genomics into routine clinical care, and driving an understanding of the role of genetics in wellness and illness.
Prior to Sema4, Ken held numerous key leadership roles at Mount Sinai Health System, where he was a Professor in the Departments of Genetics and Genomic Sciences, Medicine, Pathology, and Pediatrics, Director of the Center for Cancer Prevention and Wellness, and Associate Director of Clinical Cancer Genetics and Precision Oncology at The Tisch Cancer Institute.
Before joining Mount Sinai, Ken served as Chief of Medical Genetics and Human Genomics at Northwell Health, and was faculty for many years at the University of Chicago, where he founded the Familial Cancer Clinic. Ken has published extensively, authoring over 100 papers, reviews, and book chapters on the role of genetics in cancer risk and response to therapy. He has also been the recipient of numerous grants from the National Institutes of Health and many foundations.
Ken graduated with both a BS and an MA in Modern European History from Yale University, and then earned his MD and PhD in molecular biology from the Weil Cornell/Rockefeller/Sloan-Kettering Tri-Institutional program. He completed his medical training at the Babies and Children’s Hospital of New York (Columbia University Medical Center) and Memorial Sloan-Kettering Cancer Center, and his research training in cancer genetics at Rockefeller University.
Senior Vice President, Research
Qi Pan, PhD, has over 16 years of experience in biotech and pharmaceutical Research & Development (R&D), with an in-depth knowledge of oncology and biotherapeutic drug discovery and development. Qi serves as Senior Vice President of Research and is responsible for driving the next wave of research-led advances to augment our competitive edge with our healthcare systems and pharma partners, as well as delivering high priority research projects. She was promoted to her current role from Vice President in 2020.
Prior to Sema4, Qi was Vice President of R&D at Legend Biotech, a leading biotech company, overseeing the discovery of innovative CAR-T therapy to treat cancer. Prior to that, Qi worked at leading pharmaceutical companies, including Genentech and Boehringer Ingelheim, on biotherapeutics discovery.
Qi received her PhD from Harvard University in the field of molecular and cellular biology.
Vice President, Technology Development
Robert (Bobby) Sebra, PhD, leads Technology Development at Sema4 with a focus on technology adoption and the creation of high-throughput diagnostics. He is a leading expert in sequencing platforms and a pioneer in single molecule and single cell assay development.
Robert has published more than 150 papers in top tier journals, including Science, Cell, Nature, and The New England Journal of Medicine, and his work has led to multiple issued patents. He also serves as the Director of Technology Development at the Icahn Institute of Genomics & Multiscale Biology and an Associate Professor in the Department of Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai.